Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients

Journal of Psychopharmacology

Volumn 26, Issue 6, 2012, Pages 806-812

  Yasui Furukori, Norio ^a   Kaneda, Ayako ^a   Sugawara, Norio ^a   Tomita, Tetsu ^a   Kaneko, Sunao ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Aripiprazole; cognitive function; schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; PLACEBO; RISPERIDONE;

ADULT; ANXIETY; ARTICLE; AUTONOMIC DYSFUNCTION; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; CLINICAL ARTICLE; COGNITION; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG POTENTIATION; DRUG RESPONSE; EXCITEMENT; EXECUTIVE FUNCTION; FEMALE; HUMAN; MALE; MENTAL DISEASE; MOTOR PERFORMANCE; MOTOR SPEED; NERVOUS SYSTEM PARAMETERS; NEUROLOGIC DISEASE; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SIDE EFFECT; UDVALG FOR KLINISKE UNDERSOGELSER SIDE EFFECT RATING SCALE; VERBAL FLUENCY; VERBAL MEMORY; WORKING MEMORY;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PIPERAZINES; QUINOLONES; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA;

EID: 84862137385     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111405555     Document Type: Article

References (38)

1. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002 ; 159: 1018-1028
2. Cada DJ, Levien T, Baker DE. Aripiprazole. Hosp Pharmacy. 2003 ; 38: 247-256
3. Carpenter WT, Gold JM. Another view of therapy for cognition in schizophrenia. Biol Psychiatry. 2002 ; 51: 969-971
4. Christensen AF, Poulsen J, Nielsen CT, Bork B, Christensen A, Christensen M. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study. Acta Psychiatr Scand. 2006 ; 113: 148-153
5. Cobo Gómez JV, Fuste G, Coronas R, et al. Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Curr Drug Saf. 2008 ; 3: 210-215
6. Cohen J Statistical power analysis for the behavioral sciences. 1988 ) Statistical power analysis for the behavioral sciences, 2nd ed.Lawrence Erlbaum. Lawrence Erlbaum ; 1988 :
7. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the ''right stuff''?. Schizophr Bull. 2000 ; 26: 119-136
8. Harvey PD, Keefe RSE. Cognitive impairment in schizophrenia and implication of atypical neuroleptic treatment. CNS Spect. 1997 ; 2: 1-11
9. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology. 2003 ; 169: 404-411
10. Harvey PD, Howanitz E, Parrella M, et al. Symptoms, cognitive functioning, and adaptive skills in geriatric patients with lifelong schizophrenia: a comparison across treatment sites. Am J Psychiatry. 1998 ; 155: 1080-1086
11. Headley DB. Effects of atropine sulfate and pralidoxime chloride on visual, physiological, performance, subjective, and cognitive variables in man: a review. Mil Med. 1982 ; 147: 122-132
12. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998 ; 12: 426-445
13. Hill SK, Beers SR, Kmiec JA, Keshavan MS, Sweeney JA. Impairment of verbal memory and learning in antipsychotic-naïve patients with first-episode schizophrenia. Schizophr Res. 2004 ; 68: 127-136
14. Hill SK, Bishop JR, Palumbo D, Sweeney JA. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 2010 ; 10: 43-57
15. Hoff AL, Faustman WO, Wieneke M, et al. The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology. 1996 ; 15: 361-369
16. Hoff AL, Riordan H, O'Donnell DW, Morris L, DeLisi LE. Neuropsychological functioning of first-episode schizophreniform patients. Am J Psychiatry. 1992 ; 149: 898-903
17. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol. 2002 ; 441: 137-140
18. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002 ; 263: 763-771
19. Kaneda Y, Sumiyoshi T, Keefe R, Ishimoto Y, Numata S, Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry Clin Neurosci. 2007 ; 61: 602-609
20. Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000 ; 157: 514-520
21. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987 ; 13: 261-276
22. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007 ; 64: 633-647
23. Keefe RS, Goldberg TE, Harvey PD, Gold JM, Poe MP, Coughenour L. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res. 2004 ; 68: 283-297
24. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology. 2006 ; 187: 312-320
25. Kumari V, Corr PJ, Mulligan OF, Cotter PA, Checkley SA, Gray JA. Effects of acute administration of d-amphetamine and haloperidol on procedural learning in man. Psychopharmacology (Berl). 1997 ; 129: 271-276
26. Mohamed S, Paulsen JS, O'Leary D, Arndt S, Andreasen N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry. 1999 ; 56: 749-754
27. Mucci A, Piegari G, Galderisi S. Cognitive-enhancing effects of aripiprazole: a case report. Clin Pract Epidemol Ment Health. 2008 ; 4: 24
28. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, Bark N. Psychopathology of Schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995 ; 28: 22-31
29. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987 ; 334: 1-100
30. Sweeney JA, Haas G, Li S. Neuropsychological and eye movement abnormalities in first-episode and chronic schizophrenia. Schizophr Bull. 1992 ; 18: 283-293
31. Ramaekers JG, Louwerens JW, Muntjewerff ND, et al. Psychomotor, Cognitive, extrapyramidal, and affective functions of healthy volunteers during treatment with an atypical (amisulpride) and a classic (haloperidol) antipsychotic. J Clin Psychopharmacol. 1999 ; 19: 209-221
32. Reilly JL, Harris MS, Keshavan MS, Sweeney JA. Adverse effects of risperidone on spatial working memory in first-episode schizophrenia. Arch Gen Psychiatry. 2006 ; 63: 1189-1197
33. Reilly JL, Harris MS, Khine TT, Keshavan MS, Sweeney JA. Antipsychotic drugs exacerbate impairment on a working memory task in first-episode schizophrenia. Biol Psychiatry. 2007 ; 62: 818-821
34. Urichuk L, Prior TI, Dursun S, Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab. 2008 ; 9: 410-418
35. Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol?. Schizophr Res. 2002 ; 53: 239-248
36. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 2005 ; 8: 457-472
37. Woodward ND, Purdon SE, Meltzer HY, Zald DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res. 2007 ; 89: 211-224
38. Yasui-Furukori N, Furukori H, Sugawara N, Fujii A, Kaneko S. Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010 ; 30: 596-599